A000227 Stock Overview
Develops and markets pharmaceutical products. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Yuyu Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩10,150.00 |
52 Week High | ₩20,500.00 |
52 Week Low | ₩9,750.00 |
Beta | 0 |
11 Month Change | 0.50% |
3 Month Change | -9.38% |
1 Year Change | -42.17% |
33 Year Change | -40.12% |
5 Year Change | 7.98% |
Change since IPO | 349.12% |
Recent News & Updates
Recent updates
Shareholder Returns
A000227 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 0.8% | -3.1% | 2.9% |
1Y | -42.2% | 4.8% | -2.8% |
Return vs Industry: A000227 underperformed the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A000227 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
A000227 volatility | |
---|---|
A000227 Average Weekly Movement | 3.1% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.6% |
10% most volatile stocks in KR Market | 11.5% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A000227 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A000227's weekly volatility has decreased from 9% to 3% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1941 | 262 | Robert Yu | www.yuyu.co.kr |
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Yuyu Pharma, Inc. Fundamentals Summary
A000227 fundamental statistics | |
---|---|
Market cap | ₩67.97b |
Earnings (TTM) | ₩8.34b |
Revenue (TTM) | ₩134.79b |
8.1x
P/E Ratio0.5x
P/S RatioIs A000227 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A000227 income statement (TTM) | |
---|---|
Revenue | ₩134.79b |
Cost of Revenue | ₩83.69b |
Gross Profit | ₩51.10b |
Other Expenses | ₩42.76b |
Earnings | ₩8.34b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 515.56 |
Gross Margin | 37.91% |
Net Profit Margin | 6.19% |
Debt/Equity Ratio | 26.4% |
How did A000227 perform over the long term?
See historical performance and comparison